Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

70.40
0.0000
Post-market: 70.400.00000.00%19:30 EDT
Volume:615.74K
Turnover:43.32M
Market Cap:3.91B
PE:6.34
High:70.61
Open:70.61
Low:70.09
Close:70.40
52wk High:74.59
52wk Low:59.47
Shares:55.60M
Float Shares:55.60M
Volume Ratio:1.19
T/O Rate:1.11%
Dividend:0.81
Dividend Rate:1.15%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.40
PE(LYR):23.01

Loading ...

OverviewCompanyNewsFilings

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Sep 30

Marka S.A. Pays Twelfth Installment Under Amended Bondholder Arrangement

TIPRANKS
·
Sep 30

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

Reuters
·
Sep 30

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live
·
Sep 30

2026 Nobel Prize Preview: Scientists Behind GLP-1 Weight-Loss Drugs Emerge as Leading Contenders

Deep News
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30
More